Free Trial
→ Watch This Robotics Demo Before March 17th (From Brownstone Research) (Ad)

Anixa Biosciences 9/6/2024 Earnings Report

Anixa Biosciences logo
$3.08 -0.09 (-2.84%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Anixa Biosciences EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Date
9/6/2024
Time
After Market Closes

Conference Call Resources

Anixa Biosciences Earnings Headlines

HC Wainwright Issues Optimistic Forecast for ANIX Earnings
February 22 at 1:49 AM | americanbankingnews.com
Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at HC Wainwright
February 20 at 1:43 AM | americanbankingnews.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Anixa Biosciences, Inc.: Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
February 19 at 12:23 AM | finanznachrichten.de
Anixa Biosciences announces approval of protocol amendment for CAR-T trial
February 19 at 12:23 AM | markets.businessinsider.com
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
February 18, 2025 | prnewswire.com
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

View Anixa Biosciences Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles